The ICP34.5 protein facilitates herpes simplex virus replication by binding and activating protein phosphatase 1 (PP1) by means of a very conserved C-terminal GADD34-like region. Natural variants of the ICP34.5 differing in the number of arginines in an Arg-rich cluster at the N terminus and the number of Pro-Ala-Thr repeats in the central bridge region of the protein were cloned as fusion proteins with a reporter peptide (c-Myc or hrGFP) at the C terminus. The natural variants were obtained from strains differing in passage history, tissue culture behavior, and neuroinvasive disease potential. In transfected cells, these variants localized to different subcellular compartments. The N-terminal Arg-rich cluster acted as a cellular localization signal for discrete regions of the nucleus and cytoplasm, but the ultimate location of ICP34.5 was determined by the number of Pro-Ala-Thr repeats in the central bridge region. PP1 colocalized with the ICP34.5 variant in cells expressing the ICP34.5. The ICP34.5-mediated, herpes simplex virus strain-dependent differences in the modulation of PP1 location and function may be responsible for the strain-associated differences in tissue culture behavior and virulence of the virus.
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is important for promoting viral neurovirulence. Deletion mutants lacking ICP34.5 fail to multiply in the brain and cannot cause encephalitis after intracerebral inoculation of mice (1, 2) or is unable to replicate in dorsal root ganglia after footpad inoculation (3) . The requirement for the ICP34.5 protein for HSV-1 replication is cell type-and cell state-dependent (2-7). Deletion mutants can trigger a total shut-off of protein synthesis mediated by protein kinase R in response to HSV infection in nonpermissive cells, such as neuronal cells (6, 8) . ICP34.5 can reactivate protein synthesis by binding and activating the PP1 cellular protein phosphatase. PP1 reactivates eukaryotic initiation factor 2␣ by removing the phosphate attached by protein kinase R (9, 10). ICP34.5 can also bind to proliferating cell nuclear antigen (11) . Viruses lacking the ICP34.5 gene also show cell type-dependent deficits in virion maturation and egress (12) . Previous studies in our laboratory correlated differences in ICP34.5 sequence with the ability to cause neuroinvasive disease and also differences in tissue culture behaviors, such as plaque size, efficiency of glycoprotein processing, and viral release, for members of two families of HSV-1 strains (13) .
The ICP34.5 gene of HSV-1 is located in the inverted repeats of the unique long (UL) region of the HSV-1 genome and therefore is diploid ( Fig. 1) (14) . The coding region of the ICP34.5 gene is 0.8 -1.0 kb long with a remarkably high guanosine/ cytosine content (Ͼ80%) (13, 15) . The ICP34.5 protein consists of three regions: an N terminus with a variable number of arginines in an arginine-rich cluster; a bridge region in the center of the protein consisting of a variable number of ProAla-Thr (PAT) repeats; and a C-terminal sequence, homologous to the mammalian GADD34 (growth arrest and DNA damage) protein and murine Myd116 (myeloid differentiation primary response) protein (13, (15) (16) (17) . The GADD34-like sequence at the carboxyl terminus of the ICP34.5 protein contains a PP1 binding motif, which can activate PP1 to dephosphorylate eukaryotic initiation factor 2␣ (10, 18) . HSV-1 replication of viruses that lack the entire ICP34.5 or lack or contain specific mutations in the GADD34-like sequences is much less efficient or is inhibited in neuronal cells, including a human neuroblastoma cell line (SK-N-SH), and some noncycling primary cells (2) (3) (4) 6) . Compensatory mutation(s) can rescue virus replication in neuronal cell lines (19 -23) .
The functions associated with ICP34.5 suggest that ICP34.5 should be present in different parts of the infected cell. Proliferating cell nuclear antigen is located in the nucleus (reviewed in Ref. 24) , whereas PP1 is present in the nucleus (25, 26) and cytoplasm (27) . Interestingly, protein kinase R is also present in both the cytoplasm and the nucleus, where it is specifically localized to the nucleolus in association with ribosomes (28, 29) . A previous study using immunofluorescence microscopy suggested that ICP34.5 is present only in the cytoplasm of infected cells (30) , but in other studies, ICP34.5 was associated with cytoplasmic and nuclear fractions of infected cells (17, 31) . The presence of the Arg-rich cluster at the N terminus of ICP34.5, which resembles a putative nuclear and nucleolar targeting sequence and RNA binding sequence in the human proliferation-associated protein p120 (32) , suggests that the protein may also be present and have activity in the nucleus and nucleolus. Similar Arg-rich sequences are present at the N terminus of the I14L protein of African swine fever virus (33) , the ORF2 protein of porcine circovirus type 2 (34) and human immunodeficiency virus REV (35, 36) and act as nucleolar targeting sequences for these proteins.
In this study, the influence of the N-terminal arginine-rich region and the PAT repeat region of ICP34.5 on the cellular localization of ICP34.5 was evaluated by comparing the properties of natural variants of ICP34.5 from two families of HSV-1 strains. Although the protein sequence of the C-terminal region of ICP34.5 and most of the rest of the protein is highly conserved, a major difference between these strains is the number of PAT repeats in the middle region and the number of arginines at the N terminus of ICP34.5 ( Fig. 1) (13, 15, 37) . SP7 and LP5 are intrastrain variants isolated from a neonate with disseminated, fatal HSV-1 disease, including encephalitis. Both SP7 and LP5 have the potential to cause neuroinvasive disease in mice, but SP7 is more neuroinvasive than LP5 (13) . KOS321 and KOS79 were obtained from lip lesions of the same individual on different occasions. KOS321 is highly passaged and completely attenuated for disease (13) , and KOS79 is a low passage strain that can cause neuroinvasive disease (38) .
Due to the low expression of the ICP34.5 protein in the natural HSV-1 infection and the difficulty in the development of effective and specific antibodies against ICP34. 5 (30, 37) , an alternative approach was taken. The natural variants of the ICP34.5 gene from SP7, LP5, KOS321, and KOS79 were amplified by PCR and cloned into mammalian expression vectors to generate fusion proteins with a reporter peptide (c-Myc or hrGFP) at the C terminus. Studies of the expression and cell distribution of these recombinant proteins upon transfection into Vero cells and SK-N-SH neuroblastoma cells demonstrated that the N-terminal Arg-rich cluster was necessary and sufficient for determining ICP34.5 localization in the cell; however, the length of the PAT repeats in the middle region of the ICP34.5 variants is the ultimate determinant of the cellular location of the protein. In addition, PP1 colocalized with the ICP34.5 variant in the cells expressing ICP34.5. These studies show that the peptide sequence-determined cellular localization of ICP34.5 is a determinant in the function of the protein and hence may influence the tissue culture behavior and the virulence of HSV-1.
EXPERIMENTAL PROCEDURES

Cells and Virus
Vero cells were grown in medium 199 supplemented with 5% fetal calf serum, penicillin (100 IU/ml), streptomycin (100 g/ml), and 2.25 mM NaHCO 3 at 37°C. SK-N-SH cells were grown in Eagle's minimal essential medium supplemented with 10% fetal calf serum, 1.0 mM sodium pyruvate, and the same amount of antibiotics and NaHCO 3 as described for Vero cells.
The isolation and characteristics of the clinical strains, SP7 and LP5 (13) , and KOS79 (38) have been described. KOS321 is a plaque-purified and highly passaged strain provided by T. Holland (Wayne State University School of Medicine) (39) . The ICP34.5 deletion mutant (d34.5) and the parental McKrae strain were provided by G. C. Perng (Cedars Sinai Medical Center) (40) .
Plasmids
Recombinant ICP34.5-myc Cloned from KOS321, KOS79, SP7, and LP5-HSV-1 uses the latter of two start codons (ATG) as its start codon (15) . To truly express the ICP34.5 gene in fusion with c-Myc and His 6 , two PCR primers were synthesized in which the first start codon (ATG) and the stop codon (TAA) of the ICP34.5 gene were mutated, respectively, as indicated by the underlines: MU34 (5Ј-CTGCACGCACTT-GCTTGCCT-3Ј) and 34MU (5Ј-CTCGGGTGTAACGATAGACC-3Ј) (Sigma, Genosys). PCR amplification was performed using DNA purified from SP7-, LP5-, KOS79-, and KOS321-infected cells (Wizard Genomic DNA purification kit; Promega). Due to the high guanosine/cytosine content of the sequence, PCR was performed using the MasterAmp TM PCR optimization kit (premixture KN; Epicentre) and tfl polymerase (Epicentre) as previously described (13 primer (T34, 5Ј-CCATGGGCGCGGTCCCAACC-3Ј) was synthesized to initiate the sequence downstream of the N-terminal Arg-rich cluster from a new start codon (underlined in the T34 sequence). Truncated ICP34.5 genes were amplified by PCR using the new T34 primer and the 34MU primer (described above) and cloned into the pcDNA3.1 myc-His vector. The truncated genes derived from kos321m and sp7a are named tkos321 and tsp7, respectively. The mutant ICP34.5-myc gene was confirmed by sequencing.
Recombinant Genes with Sequences Encoding the ICP34.5 N-terminal Arg-rich Cluster Attached to the 5Ј-End of the hrGFP Gene (kos321nhrGFP, sp7nhrGFP, and kos79nhrGFP)-PCR was performed using two new primers (AR5, 5Ј-TGTGCTGGATATCTGCAGAATTCG-GCT-3Ј; ar3, AGGCCTCGAGCTGTGCGGTTGGGACCG-3Ј), which incorporate restriction enzyme sites for EcoRI and XhoI, respectively. Plasmid DNA variants including kos321m, sp7a, and kos79a were used as templates. The amplified products encompassed a 5Ј noncoding region and a leading sequence encoding the ICP34.5 N-terminal Arg-rich cluster. The products were cut with EcoRI and XhoI and ligated with an hrGFP fragment cleaved from the hrGFP vector with the same enzymes. The recombinant DNAs were named for the ICP34.5 variants, which provided the Arg-rich cluster and were sequenced to make sure that the insertion was present and in the reading frame with hrGFP.
Hybrid ICP34.5 Genes (7nKb and Kn7b)-Recombinant DNAs kos321m and sp7a were cut with NotI to produce two fragments. The small fragment, which includes the N-terminal Arg-rich cluster from one plasmid, was ligated with the large fragment containing the remaining segment of the ICP34.5 gene from the other plasmid to generate hybrid recombinant ICP34.5 DNA. The 7nKb has the first 44 amino acids from SP7 and a KOS321-like backbone, whereas the Kn7b has the first 43 amino acids from KOS321 and an SP7-like backbone. The new constructs were also sequenced.
Transient Expression of ICP34.5 Fusion Genes
Recombinant DNA was transfected into Vero cells or SK-N-SH cells using LipofectAMINE PLUS (Invitrogen). After 2 days, cells were either lysed and analyzed by Western blot or processed for immunocytochemistry.
Complementation Study
SK-N-SH cells were transfected with the ICP34.5-Myc DNA variants. After the cells reached confluence (3-4 days), the cells were grown with M199 containing 0.5% fetal calf serum for another 2-3 days and then infected by a null ICP34.5 mutant of HSV-1 (d34.5) (40) at a multiplicity of infection of 2. After 2 days, the supernatant and the infected cells were collected separately after centrifugation (12,000 ϫ g, 2 min). After freeze, thaw, and sonication, viral plaque assays were performed on Vero cells.
Antibodies
A specific antibody to ICP34.5 was developed against a peptide (AQSQVTSTPNSEPVVC) near the N terminus of the ICP34.5 protein (QCB, Hopkinton, MA). The peptide was attached to keyhole limpet hemocyanin, ovalbumin, and then tetanus toxoid, and rabbits were immunized four times with each immunogen. Sera were collected after each procedure. The antisera were purified by affinity chromatography on a peptide-agarose column. Monoclonal anti-Myc, anti-Myc-horseradish peroxidase (HRP), and goat anti-mouse TRITC (TRITC-GAM) antiserum were purchased from Invitrogen. The polyclonal anti-PP1 (FL-18) antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) used in this study was generated to a peptide present in most forms of PP1.
Western Blotting
Cells were lysed by radioimmune precipitation assay lysis buffer (100 mM NaCl, 10 mM Tris, pH 7.4, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) in the presence of a protease inhibitor mixture (Sigma) and DNase I (100 g/ml; Sigma) at 48 h after transfection. Samples were mixed with an SDS-PAGE gel loading buffer (2% SDS, 80 mM Tris, pH 6.8, 32% glycerol, 0.001% bromphenol blue, 5% ␤-mercaptoethanol) and boiled. The lysates were separated by electrophoresis on 10 -20% SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. The membranes were blotted with anti-Myc-HRP or antipeptide antibody followed by goat anti-rabbit conjugated with HRP. The signals were examined by chemiluminescence using ECL (Amersham Biosciences), and the x-ray films were digitized with an HP scanner to produce the final images.
Immunohistochemistry
Vero cells, transfected with the ICP34.5 expression vector, were seeded onto coverslips and cultured overnight. These cells were then fixed with cold acetone for 10 min. After the samples dried, they were blocked by normal mouse serum and then incubated with anti-Myc-HRP for 1 h at 37°C. After washing with PBS, these cells were stained by immersing in the disclosing reaction mixture, including diaminobenzidine tetrahydrochloride and hydrogen peroxide, for 7 min. Samples were further dehydrated by immersing sequentially in a series of graded alcohols (70, 95, and 100%) and then in xylene and mounted with Permount. Photomicrographs were obtained using an Olympus B-max 60.
Indirect Immunofluorescence
Transfected cells were fixed in 4% paraformaldehyde for 15 min and permeabilized in 0.2% Triton X-100 for 5 min. After incubation with 0.1 M glycine and 1% bovine serum albumin, the cells were incubated with anti-Myc monoclonal antibody (Invitrogen) in the presence of 1% bovine serum albumin for 1 h. After washing, these fixed cells were incubated with FITC-GAM or TRITC-GAM for another 1 h. The cells were then treated with equilibration buffer and mounted using the SlowFadelight antifade kit (Molecular Probes, Inc., Eugene, OR) and viewed by fluorescence microscopy (Olympus AX70) or confocal microscopy (Olympus IX70). The digital images were obtained and analyzed by Spot Advance software (Diagnostic instruments, Inc.). For colocalization studies, organelle-specific dyes such as propidium iodide for the nucleus, or DiOC 6 (3) for the ER (41) were used at concentrations of 5 g/ml and 2.5 g/ml, respectively, during the incubation with the secondary antibodies.
RESULTS
Strain Differences in ICP34.5 Gene/Protein Sequence-DNA encoding ICP34.5 was obtained from each of the HSV-1 strains by PCR amplification using primers from the ends of the coding sequence. The PCR products from each variant were sequenced, and the DNA sequences were aligned and converted to peptide sequences using the multiple alignment program and six frame translation programs (Sequence Launcher, BCM) (42). The ICP34.5 genes from SP7, LP5, KOS79, and KOS321 strains had extensive homology except for major sequence differences in the number of repeats of CCC GCG ACC, encoding PAT, in the middle region of the gene and the CGC repeats at the N terminus encoding a string of Arg (e.g. RRRRHRGPRRPR for LP5) ( Fig. 1) (13, 15) . The sequence of the SP7 ICP34.5 used in this and subsequent studies differs from that reported in Bower et al. (13) in that the Gly-Glu-GlyAla (GEGA) at positions 153-156 (with respect to the LP5 sequence) is present. As a result, the only difference between the SP7 and the LP5 ICP34.5 is the number of the PAT repeats, with 18 and 22, respectively. The numbers of PAT repeats in the ICP34.5 from LP5 and SP7 are larger than for other HSV-1 strains that have been reported (15, 37) . The ICP34.5 from LP5 and SP7 have 8 Arg residues in the N-terminal Arg cluster. The ICP34.5 protein from KOS79, another low passage strain, has 11 PAT repeats and nine Arg residues, while the KOS321 ICP34.5 has only three PAT repeats and seven Arg residues. Single amino acid polymorphisms are noted between SP7, LP5, and KOS321 at positions 140, 158, and 227, with respect to the LP5 sequence (13) . The KOS79 ICP34.5 has the following residues: Ala 140 , Glu 158 , and Ala 227 . In addition, the KOS79 ICP34.5 has Gly instead of Ser at position 54, Glu instead of Ala at position 161, insertion of Asp between positions 81 and 82, and deletion of Leu and Arg between positions 148 and 149. The C-terminal GADD34-like sequence is identical for all of the HSV-1 strains.
The PCR products of the ICP34.5 variants were cloned into the pcDNA3. (c-Myc epitope) indicate that the complete recombinant proteins were expressed (Fig. 2) . Although useful, the anti-peptide antibody was too weak for use in subsequent studies. The expressed ICP34.5-Myc variants differed in mobility with apparent molecular masses ranging from 40 to 60 kDa. The ICP34.5 from the LP5 and KOS321 strains were the largest and smallest, respectively, while the ICP34.5 from SP7 was slightly smaller than from LP5. The KOS79 ICP34.5 had a medium size in comparison with the proteins from LP5 and KOS321. Minor bands with faster mobility, which may correspond to degradation products, were also observed, especially for the KOS321 ICP34.5. The apparent molecular masses of these ICP34.5-Myc polypeptides are consistently larger than the predicted molecular mass that was calculated from their gene sequences (LP5-Myc, 36.1 kDa; SP7-Myc, 35 kDa; KOS79-Myc, 33.2 kDa; KOS321-Myc, 30.8 kDa) but are consistent with the differences in their genetic sequence (see Fig. 1 ). This may be due to either extensive posttranslational modification of the ICP34.5-Myc protein or more likely a structural conformation of the protein (possibly due to the PAT repeats), which affects its mobility in an SDS-PAGE electrophoresis.
Recombinant ICP34.5-Myc Complements Replication of a Null ICP34.5 Virus in SK-N-SH Cells-ICP34.5 is essential for viral replication in neuronal cells (1, 2, 6) , and replication of a null ICP34.5 mutant virus (d34.5) (40) was greatly reduced in confluent SK-N-SH cells (a neuroblastoma cell line) when the cells were grown in low concentrations of serum (data not shown). SK-N-SH cells transfected with recombinant ICP34.5-myc DNA variants were infected with d34.5 virus, and at 48 h postinfection the supernatants and cell pellets were harvested separately. Production of virus was assayed using permissive Vero cells. Only a small fraction of cells successfully expressed ICP34.5-Myc proteins upon transfection of the SK-N-SH cells. Nevertheless, the presence of KOS321 ICP34.5-Myc increased viral production by at least 15-fold in separate experiments, while the SP7 ICP34.5-Myc augmented the replication of the null virus by at least 7-fold compared with cells transfected with an antisense-KOS321 ICP34.5 sequence (Fig. 3) . The en- Cellular Localization of ICP34.5 Variants-Immunohistochemistry and immunofluorescence microscopy were performed to delineate the intracellular locations of the variants of ICP34.5. Immunohistochemistry showed a difference in the cellular localization of the SP7 and KOS321 variants of ICP34.5-Myc. The SP7 ICP34.5-Myc was localized to regions of the cytoplasm close to the nucleus, but unlike SP7 and previous reports (30) , the KOS321 ICP34.5-Myc localized predominantly to the nucleus (data not shown).
The differences in cellular localization of the ICP34.5-Myc variants could be discerned better by immunofluorescence microscopy. ICP34.5-Myc was detected with a monoclonal antibody against c-Myc followed by a secondary antibody conjugated with FITC (green). Propidium iodide (red), which binds specifically to DNA, was used to stain the nucleus. The SP7 ICP34.5-Myc concentrated in the cytoplasm, especially in perinuclear regions, while in a small fraction of the cells, very low amounts of the SP7 ICP34.5-Myc were also found in the nucleus (Fig. 4, A and C) . The localization is more clearly shown in the images in which the FITC and propidium iodide staining are merged. For cells expressing the SP7 ICP34.5-Myc, the FITC fluorescence and propidium iodide signal did not colocalize, indicating that a nuclear presence of the SP7 variant is not detectable by this technique (Fig. 4A) . In contrast, the KOS321 ICP34.5-Myc was almost exclusively in the nucleus (Fig. 4 , A and C) with the propidium iodide signal and FITC signal colocalized in the nucleus to give a yellow color. Further analysis by confocal microscopy confirmed that the expression of the KOS321 ICP34.5-Myc was limited to the nucleus (Fig. 4C) . The KOS321 ICP34.5-Myc fluorescence appeared to cover the nucleus (Fig. 4, C and D) in many of the cells, but in some cells the fluorescence appeared as an intranuclear ring (Fig. 4C) or was localized to specific regions of the nucleus or as dots within the nucleus (data not shown).
To determine whether the cytoplasmic SP7 ICP34.5-Myc was in the ER, another colocalization study was performed in which the ICP34.5-Myc was visualized with anti-Myc and TRITC-GAM (red) and the ER was stained with DiOC 6 (3) (green) (41).
The signal from DiOC 6 (3) was limited to areas surrounding the nucleus, indicative of the ER network. Some of the SP7 ICP34.5-Myc appeared to colocalize with DiOC 6 (3) upon merging of the images, as indicated by the yellow color, but much of the SP7 ICP34.5-Myc was present in other areas of the cytoplasm (Fig. 4D) .
The localization of the KOS79 and LP5 ICP34.5-Myc variants in the cell was also examined. The KOS79 ICP34.5-Myc was present in both the cytoplasm and specific regions of the nucleus (Fig. 4B) . The fluorescent signal for cells expressing the LP5 variant of ICP34.5-Myc was seen almost exclusively in the cytoplasm. The cellular distribution of the SP7, LP5, KOS79, and KOS321 ICP34.5-Myc variants in SK-N-SH cells was similar to that in Vero cells (Fig. 4C and data not shown) .
As an alternative method to study the cellular localization of the ICP34.5 variants, the distributions of hrGFP fusion proteins of the ICP34.5 variants were studied. Expression of hrGFP resulted in a diffuse fluorescence throughout the cell with complete coverage of the nucleus. The cellular distribution of the ICP34.5-hrGFP variants resembled that of the ICP34.5-Myc variants such that the cell distribution correlated with the number of PAT repeats in the proteins (Fig. 5, Table I ). The LP5 ICP34.5-hrGFP variant, with the largest number of PAT repeats (n ϭ 22), was restricted to the cytoplasm of 97% of the cells, with nuclear and cytoplasmic distribution in the remaining 3%. In cells expressing the SP7 ICP34.5-hrGFP, with 18 PAT repeats, the distribution was 88 and 12%, respectively. No cells were observed expressing only nuclear fluorescence for the LP5 or SP7 ICP34.5-hrGFP variants. The KOS79 ICP34.5-hrGFP has 11 PAT repeats, and the fluorescence was located in both the cytoplasm and in restricted areas within the nucleus. For the KOS79 ICP34.5-hrGFP, 66% of the ICP34.5-expressing cells had GFP in both nuclear and cytoplasmic compartments, 28% of the cells had expression only in the nucleus, and the remaining 6% of the cells expressed GFP only in the cytoplasm. The KOS321 ICP34.5-hrGFP, with the smallest number of PAT repeats (n ϭ 3), was predominantly in the nucleus, with 90% of the cells expressing only nuclear fluorescence and the other 10% of the cells with the GFP signal in both the nucleus and cytoplasm. The nuclear immunofluorescence for all of the variants of GFP-ICP34.5 was localized to discrete regions. The distribution of the different ICP34.5-hrGFP variants was not changed by infection of the cells with HSV-1 SP7 virus (data not shown). These findings indicate that ICP34.5 variants with a long PAT region are more likely to be absent from the nucleus.
Role of the N-terminal Arg-rich Cluster for Cellular Localization of the ICP34.5 Proteins-To determine the role of the Arg-rich clusters for the cellular localization of ICP34.5, constructs lacking the N-terminal 18 amino acid residues (including the Arg-rich cluster) were prepared for ICP34.5 from KOS321 and SP7. The expression and size of the truncated proteins (tkos321 and tsp7) were confirmed by Western blot analysis. Both truncated proteins exhibited a faster mobility than their parental proteins (Fig. 6A) . The truncated ICP34.5-Myc variants were able to complement the replication of the d34.5 virus in SK-N-SH cells to levels similar to the intact ICP34.5-Myc variants (Fig. 3) , indicating that the protein was functional.
Cells expressing the truncated KOS321 ICP34.5-Myc protein exhibited a diffuse fluorescence throughout the cell. The cytoplasmic distribution of the tsp7 protein was more diffuse than for SP7, and unlike tkos321, it excluded the nucleus (Fig. 6B) . These results indicate that the N terminus, which includes the Arg-rich sequence, is necessary for the characteristic cellular distribution of the KOS321 and SP7 variants of ICP34.5. The exclusion of tsp7 from the nucleus indicates that other sequences in the SP7 ICP34.5 also influence the distribution of the SP7 variant.
Whether the N-terminal Arg-rich cluster is sufficient to determine the cellular distribution of ICP34.5 was tested by comparing the cellular distributions of hrGFP and fusion proteins of the Arg-rich clusters from three different ICP34.5 variants (KOS321, SP7, and KOS79) inserted at the N terminus of the hrGFP. These clusters have 7, 8, or 9 Arg residues, respectively. The unmodified hrGFP diffused throughout the cell, including the nucleus. The fluorescent signal for hrGFP modified by the N-terminal attachment of Arg-rich clusters from any of the ICP34.5 variants was distributed within the cytoplasm and to discrete regions of the nucleus, resembling the nucleolus (Fig. 7) . The cellular targeting of hrGFP was the same regardless of the number (n ϭ 7, 8, or 9) of Arg residues in the cluster (data not shown). This experiment indicates that the N-terminal Arg-rich cluster from ICP34.5 directs proteins to the cytoplasm and discrete regions of the nucleus, but it is not the sole determinant for the cellular localization of the ICP34.5 variants.
The Localization of the ICP34.5 Protein Is Influenced by the Number of PAT Repeats-To confirm that the number of PAT repeats in an ICP34.5 variant determines the cellular localization of the protein, hybrid ICP34.5-Myc proteins were constructed in which the N termini of the SP7 and the KOS321 ICP34.5 variants were exchanged at amino acid 44 of the SP7 variant of ICP34.5. The 7nKb ICP34.5-Myc was prepared with an SP7-like N-terminal Arg-rich cluster (8 Arg residues) and a KOS321 backbone (three PAT repeats in the bridge region). The Kn7b ICP34.5-Myc was prepared with a KOS321-like Nterminal Arg-rich cluster (7 Arg residues) and an SP7 backbone (18 PAT repeats). The Kn7b ICP34.5-Myc was distributed primarily within the cytoplasm, especially to perinuclear regions, and in some cells a small amount was present in specific regions of the nucleus, similar to the SP7 ICP34.5-Myc. In contrast, the 7nKb ICP34.5-Myc was in the nucleus, similar to the KOS321 ICP34.5-Myc (Fig. 8) . This indicates that although the N-terminal Arg-rich clusters provide a cellular localization signal for the cytoplasm and discrete regions of the nucleus, the final location of ICP34.5 is determined by other regions of the protein. Since the major difference in ICP34.5 structure between the different variants is the number of the PAT repeats, it is most likely that the PAT repeats are the determinant of the final cellular location of ICP34.5.
ICP34.5 Directs the Cellular Localization of PP1-ICP34
.5 binds to PP1 through the GADD34-like C terminus of the protein (9, 10, 18) . The intracellular location of PP1 was examined by immunofluorescence using a polyclonal anti-PP1 antibody, which recognizes most forms of PP1, and visualized with FITC-goat anti-rabbit (green). ICP34.5-Myc was visualized with TRITC-GAM (red) in cells transfected with the SP7 or KOS321 variants. In cells that did not express the ICP34.5 protein, the PP1 exhibited a diffuse intracellular fluorescence that included the nucleus. In contrast, the distribution of PP1 fluorescence was mainly in the cytoplasm and colocalized with the fluorescence of ICP34.5 in cells expressing the SP7 ICP34.5-Myc variant. Some nuclear fluorescence of PP1 was also present and may be due to PP1 isoforms that do not bind to the SP7 ICP34.5. Similarly, the distribution of PP1 in cells expressing the KOS321 ICP34.5-Myc variant was concentrated in the nucleus, and for some cells, the PP1 and ICP34.5 were in discrete regions of the nucleus and, to a minor extent, in the cytoplasm (Fig. 9 ).
DISCUSSION
The functions attributed to ICP34.5 have been associated with the C-terminal GADD34-like sequences (9 -11, 18, 43) . By comparing the cellular distribution of the natural variants of ICP34.5 expressed as fusion proteins with C-terminal c-Myc or hrGFP, we show that the ICP34.5 variants are localized to different cellular compartments and the Arg-rich cluster at the N terminus and the PAT repeats in the middle-bridge region of the protein work together to manipulate the cellular distribution of the ICP34.5.
Although the properties of the fusion proteins and their expression differ somewhat from the native protein during a natural infection, the possible influence of the additional sequences on the properties of the ICP34.5 is discounted by the following: both the c-Myc-His 6 and hrGFP fusion proteins exhibited similar cell distributions for each of the recombinant ICP34.5 variant proteins; the fusion proteins were also shown to be functional by their ability to enhance the replication of an ICP34.5 null virus (d34.5) (40) in SK-N-SH neuroblastoma cells; and the cellular distribution of the different ICP34.5 variant-hrGFP fusion proteins was not changed by infection of the cells with HSV-1.
The Arg-rich cluster at the N terminus of ICP34.5 (e.g. RRRRHRGPRRPR, for LP5) acts as a cellular localization signal to direct the ICP34.5 into the cytoplasm, especially to perinuclear regions, and to specific regions of the nucleus, resembling the nucleolus. Without the Arg-rich cluster, the KOS321 variant of ICP34.5 (tkos321) exhibits a diffuse cellular distribution unlike the distribution of any of the variant ICP34.5 proteins. Similarly, the lack of an N-terminal Arg-rich cluster for the p32 isoform of the human I-mfa domain-containing protein deprives this protein of a nucleolar targeting mechanism (44) . The ability of the Arg-rich cluster to direct hrGFP to specific cytoplasmic, nuclear, and discrete nuclear sites resembling the nucleolus indicates that the sequence can be sufficient to direct ICP34.5 to these cellular regions. The Argrich clusters with 7, 8, or 9 arginines, corresponding to the ICP34.5 variants, were equivalent in their ability to target hrGFP. Arg-rich clusters, like that present in ICP34.5, act as nuclear and nucleolar localization sequences for other proteins, including the ORF2 protein in porcine circovirus type 2 (34), the catalytic subunit of HSV-1 DNA polymerase (45), the p14ARF (alternative reading frame) tumor suppressor (46), nucleolar p120 protein (32) , and the I14L protein of African swine fever virus (33), a protein that resembles ICP34.5 in several ways. For the REV protein of human immunodeficiency virus, an arginine-rich cluster serves as both a nuclear/nucleolar targeting sequence and an RNA binding sequence (35, 36) . Although the reason for ICP34.5 to be in the nucleus and the cytoplasm is not known, it is interesting that protein kinase R (28, 29) and PP1, the ligand of ICP34.5 (24 -26) , are present in the nucleus and/or nucleolus in addition to the cytoplasm.
The presence of an Arg-rich cluster appears to be important for wild type levels of neurovirulence in mouse models of infection (1, 47) despite the ability of the ICP34.5 lacking the Nterminal Arg-rich cluster (tICP34.5) to promote the growth of a deletion mutant in neuroblastoma cells ( Ref. 16; Fig. 3 ). The position of the Arg-rich cluster with respect to the N terminus of ICP34.5 also appears to be important, since a mutant virus with a new epitope (16 amino acids) added to the N terminus of ICP34.5 was 10 times less neurovirulent (1), whereas another mutant virus with an 8-amino acid deletion downstream of the cluster maintained its neurovirulence and the ability to replicate in neuronal cells (2) .
Stark differences in the distribution of the ICP34.5 variants correlated best with the number of PAT repeats. The LP5 and KOS321 variants of ICP34.5 have the longest (n ϭ 22) and the shortest (n ϭ 3) PAT repeats, respectively, reported for HSV-1, and they show the greatest contrast in cellular distribution. The KOS321 ICP34.5 was present almost exclusively in the nucleus, while the LP5 ICP34.5 variant was limited almost exclusively to the cytoplasm. Similar to the LP5 variant, the SP7 ICP34.5, with 18 PAT repeats, was primarily in the cytoplasm, but unlike LP5, there was a small amount of ICP34.5 present in nuclei. The tsp7, lacking the N-terminal Arg region, but with the 18 PAT repeats, was restricted from the nucleus. The KOS79 ICP34.5, with an intermediate number of PAT repeats (n ϭ 11), distributed to both the cytoplasm and to discrete regions of the nucleus, as if to have characteristics of both the KOS321 and LP5 variants. Interestingly, most variants of ICP34.5 have more than five PAT repeats (15, 37) . The PAT region of ICP34.5 modulates the targeting ability of the Arg-rich cluster at the N terminus of ICP34.5 and, as a result, determines where the protein goes in the cell.
The longer PAT repeat regions, as for SP7 and LP5, are likely to form structures consisting of a rigid collagen-like helix with 9 amino acids per turn and with the threonine residues facing the outside surface (as suggested by a computer model (SpartanPro; Wave Function, Inc.)). Such an ICP34.5 protein might adopt a dumbbell-like shape with the N-and C-terminal globular regions bridged by the rod formed by PAT repeats. The prediction of an extended structure is supported by the slower SDS-PAGE mobility for the ICP34.5 protein variants than would be expected from their molecular weights (Fig. 2) . The proline-directed structure of the PAT repeats would not be extensively disrupted even upon boiling in SDS. The structure formed by a long sequence of PAT repeats, as present in the SP7 and LP5 variants, may prevent the nuclear entry of the ICP34.5, whereas an intermediate number of PAT repeats may hinder but not prevent the nuclear presence of ICP34.5, as seen for the KOS79 variant with its 11 PAT repeats. The combination of the targeting signal from the N-terminal arginine cluster and the modulating effect of the PAT region appear to be the primary determinants of the amount of ICP34.5 localized to the nucleus.
The strain-dependent distributions of ICP34.5 were also reflected in the distribution of its primary ligand, PP1. The PP1 in cells expressing the KOS321 variant of ICP34.5 was concentrated to discrete sites in the nucleus, the sites where the ICP34.5 was localized, rather than the disperse distribution of PP1 of the nontransfected cells. Similarly, the PP1 in cells expressing the SP7 variant of ICP34.5 was concentrated in the cytoplasm rather than the nucleus. The ICP34.5 variants, acting as cellular PP1 binding proteins, either concentrate or deliver the PP1 to specific sites in the cell, either nuclear or cytoplasmic. Cellular proteins, like PNUT (25) , which binds to PP1 and localizes it to the nucleus, also determine the nuclear distribution of PP1. Binding of ICP34.5 to PP1 may deliver the PP1 to specific sites in the cell in support of important viral function(s).
The number of PAT repeats in the bridge region of ICP34.5 appears to be the structural determinant that delineates the distribution of ICP34.5 and PP1 within the cell. As a result, the greatest differences in PP1 distribution and its functions would be expected between HSV strains with ICP34.5 variants containing extreme numbers of PAT repeats, such as for KOS321 and LP5 or SP7. This difference may be accentuated during natural infection because the levels of ICP34.5 are low.
PP1 isoforms have been attributed with functions other than the dephosphorylation and reactivation of the eukaryotic initiation factor 2␣ protein after it is phosphorylated in response to HSV infection or interferon ␣ action (43) . For example, in yeast, PP1 is essential for membrane fusion processes that are involved in vesicular transport from the ER to the Golgi apparatus (48) , and in Xenopus extracts, inhibition of PP1 increased formation of ER networks (27) . These actions of PP1 may be relevant to our previous studies in which we correlated the number of PAT repeats in ICP34.5 for a particular HSV-1 strain with efficiency of glycoprotein processing and virion release (13) . These processes involve vesicular transport. The KOS321, SLP5, and SLP10 strains are readily released from infected cells and have only three PAT repeats in ICP34.5. In contrast, the processing of glycoproteins of the SP7 strain of HSV-1 (the parent strain of SLP5 and SLP10), which has 18 PAT repeats, is limited to steps that occur in the ER, and the virus is more cell-associated. The neuroinvasive disease potential of these strains also correlates with the number of PAT repeats such that the KOS321-like viruses are completely attenuated and the viruses with larger numbers of PAT repeats are virulent (13, 38) . These correlations suggest a connection between the sequence-determined cellular distribution of ICP34.5; its interaction with its target proteins, PP1, possibly proliferating cell nuclear antigen, or other proteins; and the influence of ICP34.5 on virus replication and pathogenesis.
